ES2656489T3 - Métodos para genotipos específicos para tratar sujetos humanos usando 4-metilpirazol - Google Patents
Métodos para genotipos específicos para tratar sujetos humanos usando 4-metilpirazol Download PDFInfo
- Publication number
- ES2656489T3 ES2656489T3 ES10786733.5T ES10786733T ES2656489T3 ES 2656489 T3 ES2656489 T3 ES 2656489T3 ES 10786733 T ES10786733 T ES 10786733T ES 2656489 T3 ES2656489 T3 ES 2656489T3
- Authority
- ES
- Spain
- Prior art keywords
- adh2
- aldh2
- subjects
- methylpyrazole
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- RIKMMFOAQPJVMX-UHFFFAOYSA-N fomepizole Chemical compound CC=1C=NNC=1 RIKMMFOAQPJVMX-UHFFFAOYSA-N 0.000 title abstract description 22
- 238000000034 method Methods 0.000 title abstract description 7
- 229960004285 fomepizole Drugs 0.000 title abstract 6
- 102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 abstract description 26
- 101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 abstract description 26
- 102000009645 Mitochondrial Aldehyde Dehydrogenase Human genes 0.000 abstract description 23
- 108010009513 Mitochondrial Aldehyde Dehydrogenase Proteins 0.000 abstract description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 19
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 abstract description 17
- 150000003839 salts Chemical class 0.000 abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 4
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 4
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 4
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000007399 DNA isolation Methods 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- IKHGUXGNUITLKF-MZCSYVLQSA-N 1,2,2,2-tetradeuterioethanone Chemical compound [2H]C(=O)C([2H])([2H])[2H] IKHGUXGNUITLKF-MZCSYVLQSA-N 0.000 description 1
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical class NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 1
- WVVOBOZHTQJXPB-UHFFFAOYSA-N N-anilino-N-nitronitramide Chemical compound [N+](=O)([O-])N(NC1=CC=CC=C1)[N+](=O)[O-] WVVOBOZHTQJXPB-UHFFFAOYSA-N 0.000 description 1
- WQKBEGVHVPMTRV-UHFFFAOYSA-N [N+](=O)([O-])N(NC1=CC=CC=C1)[N+](=O)[O-].C(C)=O Chemical compound [N+](=O)([O-])N(NC1=CC=CC=C1)[N+](=O)[O-].C(C)=O WQKBEGVHVPMTRV-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18588409P | 2009-06-10 | 2009-06-10 | |
| US185884P | 2009-06-10 | ||
| PCT/US2010/037879 WO2010144518A1 (en) | 2009-06-10 | 2010-06-09 | Genotype specific methods for treating human subjects using 4- methylpyrazole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2656489T3 true ES2656489T3 (es) | 2018-02-27 |
Family
ID=43309203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10786733.5T Active ES2656489T3 (es) | 2009-06-10 | 2010-06-09 | Métodos para genotipos específicos para tratar sujetos humanos usando 4-metilpirazol |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20120252857A1 (https=) |
| EP (2) | EP2440049B1 (https=) |
| JP (2) | JP5836270B2 (https=) |
| KR (3) | KR20120032523A (https=) |
| CN (2) | CN106943398A (https=) |
| AU (1) | AU2010258821B2 (https=) |
| DK (1) | DK2440049T3 (https=) |
| ES (1) | ES2656489T3 (https=) |
| NO (1) | NO2440049T3 (https=) |
| PT (1) | PT2440049T (https=) |
| SG (1) | SG176734A1 (https=) |
| TW (1) | TWI523653B (https=) |
| WO (1) | WO2010144518A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8901484B2 (en) * | 2012-04-27 | 2014-12-02 | Sanofi-Aventis Deutschland Gmbh | Quantification of impurities for release testing of peptide products |
| WO2017072828A1 (ja) * | 2015-10-26 | 2017-05-04 | 株式会社日立製作所 | デバッグを支援する方法及び計算機システム |
| WO2019209123A1 (en) * | 2018-04-27 | 2019-10-31 | Remedius Biotech Limited | Diagnosis, risk reduction and treatment of conditions associated with elevated aldehyde levels |
| CN109381458B (zh) * | 2018-12-16 | 2020-09-01 | 李志武 | 甲吡唑及其盐在制备抗癫痫药物中的用途 |
| CN120475912A (zh) | 2022-12-01 | 2025-08-12 | 匹克生物酶高科技有限公司 | 用于改善行为和运功功能的新型醛脱氢酶食品和药剂组合物 |
| AU2023402120A1 (en) * | 2022-12-01 | 2025-06-12 | PICOENTECH Co., LTD. | Food and pharmaceutical composition for detoxifying endogenous aldehydes |
| WO2024117701A1 (en) * | 2022-12-01 | 2024-06-06 | PICOENTECH Co., LTD. | Food and drug composition containing novel aldehyde dehydrogenase for suppressing tremor or movement disorder |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106620A (en) | 1980-12-22 | 1982-07-02 | Takara Shuzo Co Ltd | Ameliorant for alcoholic metabolism |
| GB0404481D0 (en) | 2004-02-28 | 2004-03-31 | Rhodia Cons Spec Ltd | Soap control agent |
| WO2005084392A2 (en) * | 2004-03-03 | 2005-09-15 | Convivia | 4-methylpyrazole formulations for inhibiting ethanol intolerance |
| WO2009058874A1 (en) * | 2007-11-02 | 2009-05-07 | Monte Woodow C | Methods and materials for treating or preventing diseases/disorders mediated by alcohol dehydrogenase |
-
2010
- 2010-06-09 PT PT107867335T patent/PT2440049T/pt unknown
- 2010-06-09 EP EP10786733.5A patent/EP2440049B1/en not_active Not-in-force
- 2010-06-09 ES ES10786733.5T patent/ES2656489T3/es active Active
- 2010-06-09 AU AU2010258821A patent/AU2010258821B2/en not_active Ceased
- 2010-06-09 EP EP17206781.1A patent/EP3311811A1/en not_active Withdrawn
- 2010-06-09 KR KR1020127000590A patent/KR20120032523A/ko not_active Ceased
- 2010-06-09 SG SG2011090883A patent/SG176734A1/en unknown
- 2010-06-09 KR KR1020167023761A patent/KR20160147709A/ko not_active Ceased
- 2010-06-09 NO NO10786733A patent/NO2440049T3/no unknown
- 2010-06-09 KR KR1020147029368A patent/KR20140138318A/ko not_active Ceased
- 2010-06-09 CN CN201710098759.1A patent/CN106943398A/zh active Pending
- 2010-06-09 CN CN2010800352852A patent/CN102458121A/zh active Pending
- 2010-06-09 US US13/376,933 patent/US20120252857A1/en not_active Abandoned
- 2010-06-09 DK DK10786733.5T patent/DK2440049T3/en active
- 2010-06-09 JP JP2012515088A patent/JP5836270B2/ja not_active Expired - Fee Related
- 2010-06-09 TW TW099118855A patent/TWI523653B/zh not_active IP Right Cessation
- 2010-06-09 WO PCT/US2010/037879 patent/WO2010144518A1/en not_active Ceased
-
2012
- 2012-06-21 US US13/529,695 patent/US20120322843A1/en not_active Abandoned
-
2015
- 2015-03-24 JP JP2015060341A patent/JP2015155422A/ja active Pending
-
2016
- 2016-09-20 US US15/270,842 patent/US20170007578A1/en not_active Abandoned
-
2017
- 2017-10-19 US US15/788,504 patent/US20180098964A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20120322843A1 (en) | 2012-12-20 |
| CN102458121A (zh) | 2012-05-16 |
| AU2010258821A1 (en) | 2012-01-19 |
| KR20140138318A (ko) | 2014-12-03 |
| US20120252857A1 (en) | 2012-10-04 |
| US20180098964A1 (en) | 2018-04-12 |
| TWI523653B (zh) | 2016-03-01 |
| EP2440049A1 (en) | 2012-04-18 |
| AU2010258821B2 (en) | 2016-03-10 |
| EP3311811A1 (en) | 2018-04-25 |
| KR20120032523A (ko) | 2012-04-05 |
| US20170007578A1 (en) | 2017-01-12 |
| CN106943398A (zh) | 2017-07-14 |
| JP2015155422A (ja) | 2015-08-27 |
| PT2440049T (pt) | 2018-03-05 |
| EP2440049A4 (en) | 2012-12-05 |
| DK2440049T3 (en) | 2018-02-19 |
| WO2010144518A1 (en) | 2010-12-16 |
| JP2012529526A (ja) | 2012-11-22 |
| JP5836270B2 (ja) | 2015-12-24 |
| KR20160147709A (ko) | 2016-12-23 |
| TW201110966A (en) | 2011-04-01 |
| EP2440049B1 (en) | 2017-12-13 |
| SG176734A1 (en) | 2012-01-30 |
| NO2440049T3 (https=) | 2018-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2656489T3 (es) | Métodos para genotipos específicos para tratar sujetos humanos usando 4-metilpirazol | |
| Yu et al. | miRNA-144 induces microglial autophagy and inflammation following intracerebral hemorrhage | |
| Noguchi et al. | Gefitinib initiates sterile inflammation by promoting IL-1β and HMGB1 release via two distinct mechanisms | |
| Sousa et al. | First liquid chromatography method for the simultaneous determination of levofloxacin, pazufloxacin, gatifloxacin, moxifloxacin and trovafloxacin in human plasma | |
| Hwang et al. | Long-term storage limits PCR-based analyses of malaria parasites in archival dried blood spots | |
| CN101892311B (zh) | 高血压易感基因的单核苷酸多态性位点rs7550536的检测方法及检测试剂盒 | |
| Mahajan et al. | Morphine exacerbates HIV-1 viral protein gp120 induced modulation of chemokine gene expression in U373 astrocytoma cells | |
| LLerena et al. | Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients | |
| KR20210143878A (ko) | 요로상피세포암종의 치료를 위한 fgfr 티로신 키나제 저해제 | |
| CN106987618A (zh) | 与他汀类药物个体化用药相关的多个基因单核苷酸多态性位点组合及其应用 | |
| Barnadas et al. | Significant geographical differences in prevalence of mutations associated with Plasmodium falciparum and Plasmodium vivax drug resistance in two regions from Papua New Guinea | |
| Gomes et al. | Validation of quantitative real-time PCR for the in vitro assessment of antileishmanial drug activity | |
| Keita et al. | Antibacterial and antiplasmodial activities of tannins extracted from Zizyphus mauritiana in Mali | |
| Shi et al. | Study on the mechanism of Trichosanthes kirilowii Maxim. against COPD based on serum chemical composition analysis, network pharmacology, and experimental study | |
| US20180110785A1 (en) | Methods and compositions for ameliorating symptoms associated with chromosomal abnormalities | |
| Dindagur et al. | Thrombophilic gene polymorphisms in puerperal cerebral veno-sinus thrombosis | |
| Djurdjevic et al. | High-performance liquid chromatographic assay of fleroxacin in human serum using fluorescence detection | |
| Skogerboe | Molecular biology techniques | |
| EP3200783B1 (en) | Erythromelalgia treatment | |
| Hashemi et al. | Association between NPHS1 and NPHS2 gene variants nephrotic syndrome in children | |
| Kim et al. | Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan | |
| CN101892297B (zh) | 高血压易感基因单核苷酸多态性位点的检测方法及其试剂盒 | |
| Dörrie et al. | An improved method for RNA isolation and removal of melanin contamination from melanoma tissue: implications for tumor antigen detection and amplification | |
| CN105925679A (zh) | 利用rs4680多态性检测氯氮平和利培酮用药效果的试剂盒 | |
| Muhammad et al. | Plasmodium falciparum multidrug Resistance-1 (pfmdr1) gene mutation in adults malaria patients attending Murtala Muhammad specialist hospital Kano, Northwest Nigeria |